Tumor Profiling Market Report 2026

The tumor profiling market size has grown rapidly in recent years. It will grow from $11.18 billion in 2025 to $12.31 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising cancer incidence rates, expansion of molecular diagnostics laboratories, increasing use of targeted cancer therapies, advancements in sequencing technologies, growth of oncology research funding.

The tumor profiling market size is expected to see strong growth in the next few years. It will grow to $17.96 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing adoption of precision oncology, growing demand for personalized cancer treatment, advancements in bioinformatics platforms, expansion of companion diagnostics, rising investments in translational cancer research. Major trends in the forecast period include increasing adoption of next-generation sequencing, rising use of multi-omics profiling approaches, growing integration of AI-based data interpretation, expansion of personalized oncology applications, enhanced focus on biomarker discovery.

The increasing demand for personalized medicine is expected to propel the growth of the tumor profiling market in the coming years. Personalized medicine involves tailoring healthcare treatments to the unique characteristics of individual patients. This rising demand is driven by patients and clinicians seeking more precise therapies that deliver improved outcomes and fewer side effects compared with conventional treatment approaches. Tumor profiling supports personalized medicine by identifying specific genetic alterations and biomarkers within a patient’s tumor, enabling the selection of targeted therapies while minimizing unnecessary toxicity. For example, in February 2024, the Personalized Medicine Coalition reported that personalized medicines accounted for more than one-third of all new drug approvals in 2023, marking the fourth consecutive year this milestone was achieved. As a result, the growing adoption of personalized medicine is fueling the expansion of the tumor profiling market.

Leading companies in the tumor profiling market are concentrating on the development of advanced technologies, such as artificial intelligence (AI)-powered diagnostic solutions, to improve precision and efficiency in cancer care. Artificial intelligence refers to the application of advanced computational techniques to analyze complex genomic, proteomic, and clinical datasets, enabling faster diagnoses, more personalized treatment strategies, and improved monitoring of disease progression. For instance, in January 2025, Panakeia Technologies Ltd., a U.K.-based company specializing in AI-driven cancer diagnostic software, launched PANProfiler Colon, an AI-powered solution designed to profile critical molecular biomarkers, including microsatellite instability (MSI) and mismatch repair deficiency (dMMR), from hematoxylin and eosin (H&E)-stained images of colon cancer tissue samples. This digital tool enables rapid and accurate tumor molecular profiling, which is essential for colorectal cancer diagnosis, identification of Lynch syndrome, and informed personalized treatment decisions.

In February 2024, Myriad Genetics Inc., a U.S.-based provider of genetic testing and precision medicine solutions, acquired assets from Intermountain Precision Genomics (IPG) for an undisclosed amount. Through this acquisition, Myriad expanded its precision oncology capabilities by adding the Precise Tumor test, the Precise Liquid test, and IPG’s CLIA-certified laboratory in St. George, Utah, to its portfolio, with the goal of enhancing patient care. Intermountain Precision Genomics is a U.S.-based molecular diagnostics division focused on genomic testing and tumor profiling.

Major companies operating in the tumor profiling market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., GenScript Biotech Corporation, NeoGenomics Inc., Caris Life Sciences Inc., Tempus Inc., Foundation Medicine Inc., NanoString Technologies Inc., Personalis Inc., Boreal Genomics Inc., Strand Life Sciences Pvt. Ltd., HTG Molecular Diagnostics Inc., Lucence Health Inc., Predictive Oncology Inc.

North America was the largest region in the tumor profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the tumor profiling market by increasing costs of imported sequencing instruments, reagents, bioinformatics hardware, and specialized laboratory consumables. Oncology centers and research institutions in North America and Europe are most affected due to reliance on high-end imported technologies, while Asia-Pacific faces cost pressures on laboratory expansion. These tariffs are increasing testing costs and slowing adoption in smaller labs. However, they are also encouraging local manufacturing of diagnostic reagents, regional sequencing platform development, and expansion of domestic molecular diagnostics capabilities.

The tumor profiling market research report is one of a series of new reports that provides tumor profiling market statistics, including tumor profiling industry global market size, regional shares, competitors with a tumor profiling market share, detailed tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the tumor profiling industry. This tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tumor profiling involves a range of techniques used to examine and characterize the genetic and molecular attributes of a tumor, enabling the identification of specific mutations, gene expression patterns, and other molecular features of cancer cells. This approach provides essential insights into tumor biology, supports treatment decision-making, and facilitates the development of personalized therapies.

The primary techniques used in tumor profiling include genomics, proteomics, epigenetics, and metabolomics. Genomics focuses on the analysis of the genetic material (DNA) of cancer cells to identify the genetic alterations involved in tumor development and progression. It employs technologies such as sequencing methods, quantitative polymerase chain reaction (qPCR), immunohistochemistry, in situ hybridization (ISH), and microarray, which are applied in areas including personalized cancer medicine, oncological diagnostics, and research.

The tumor profiling market includes revenues earned by entities by providing services such as biomarker testing, methylation profiling, and clinical trial matching. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor profiling market also includes sales of liquid biopsy kits, immunohistochemistry (IHC) kits, and methylation profiling kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.